Vemurafenib in patients with BRAF(V600) mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

BACKGROUND: The BRIM-3 trial showed improved progression-free survival (PFS) and overall survival (OS) for vemurafenib compared with dacarbazine in treatment-naive patients with BRAF(V600) mutation–positive metastatic melanoma. We present final OS data from BRIM-3. PATIENTS AND METHODS: Patients wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Chapman, P B, Robert, C, Larkin, J, Haanen, J B, Ribas, A, Hogg, D, Hamid, O, Ascierto, P A, Testori, A, Lorigan, P C, Dummer, R, Sosman, J A, Flaherty, K T, Chang, I, Coleman, S, Caro, I, Hauschild, A, McArthur, G A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834156/
https://www.ncbi.nlm.nih.gov/pubmed/28961848
http://dx.doi.org/10.1093/annonc/mdx339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834156/
https://www.ncbi.nlm.nih.gov/pubmed/28961848
http://dx.doi.org/10.1093/annonc/mdx339

Ejemplares similares